Locally advanced rectal cancer: the 2026 map
First question
In the first 12 patients with dMMR rectal cancer treated with dostarlimab alone, 12 of 12 had a complete clinical response.Cercek 2022. No patient needed chemoradiation or surgery during follow-up. 49 of 49 rectal patients in the 2025 update (Cercek 2025). Mismatch repair proteins (MLH1, MSH2, MSH6, PMS2) are checked on the biopsy by immunohistochemistry: all four present means proficient.
Chemoradiation: the drug during radiation
Mixing up the two is the classic prescribing error. The radiosensitizer dose is lower because radiation adds its own toxicity to the same bowel.
Total neoadjuvant therapy: three trials, two orders
Sources
Retrieved from PubMed, read on Oct 15, 2026.
- Cercek A, et al. PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N Engl J Med 2022. doi:10.1056/NEJMoa2201445
- Hofheinz RD, et al. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, non-inferiority, phase 3 trial. Lancet Oncol 2012. doi:10.1016/S1470-2045(12)70116-X
- Bahadoer RR, et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (RAPIDO). Lancet Oncol 2021. doi:10.1016/S1470-2045(20)30555-6
- Conroy T, et al. Neoadjuvant FOLFIRINOX and preoperative chemoradiotherapy for locally advanced rectal cancer (PRODIGE 23). Lancet Oncol 2021. doi:10.1016/S1470-2045(21)00079-6
- Garcia-Aguilar J, et al. Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy (OPRA). J Clin Oncol 2022. doi:10.1200/JCO.22.00032
- Cercek A, et al. Nonoperative management of mismatch repair-deficient tumors. N Engl J Med 2025. doi:10.1056/NEJMoa2404512
- Schrag D, et al. Preoperative treatment of locally advanced rectal cancer. N Engl J Med 2023. doi:10.1056/NEJMoa2303269
- Dijkstra EA, et al. Locoregional failure during and after short-course radiotherapy followed by chemotherapy and surgery compared with long-course chemoradiotherapy and surgery (RAPIDO). Ann Surg 2023. doi:10.1097/SLA.0000000000005799
- Conroy T, et al. Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: 7-year results of PRODIGE 23. Ann Oncol 2024. doi:10.1016/j.annonc.2024.06.019
Anterior mediastinal mass in a young adult
The short differential
Markers: blood, not urine
Order of operations
Markers, tissue, steroids, in that order.Steroids before tissue: lymphoma cells die within hours and the biopsy comes back as necrosis. In a pediatric series, steroids before biopsy compromised or delayed the diagnosis in 5 of 23 children (22%), and 3 of 23 never got a definitive diagnosis (Borenstein 2000). One dose of dexamethasone "for the swelling" can cost a week and a second procedure.
Before the biopsy, also order
Sources
Retrieved from PubMed, read on Oct 15, 2026.
- Blank RS, de Souza DG. Anesthetic management of patients with an anterior mediastinal mass. Can J Anaesth 2011. doi:10.1007/s12630-011-9539-x
- International Germ Cell Cancer Collaborative Group. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 1997. doi:10.1200/JCO.1997.15.2.594
- Borenstein SH, et al. The effects of prebiopsy corticosteroid treatment on the diagnosis of mediastinal lymphoma. J Pediatr Surg 2000. doi:10.1053/jpsu.2000.6945
Reading the chemistry panel in the first week of chemotherapy
Trap 1: "the bilirubin is still rising, is it progressing?"
Progression is an imaging diagnosis (RECIST). In practice the first scan is after 2 cycles, around 6 weeks. Changing a regimen on day 7 of the first cycle throws away the drug most likely to work.
Trap 2: one enzyme jumps, the others do not move
Hemolysis is the most common preanalytic error in the hospital lab.Lippi 2006: hemolysis significantly raises AST, LDH and potassium in routine chemistry. A single discordant value with no clinical change is a repeat, not an order.
Trap 3: dosing the next cycle on a failing liver
Sources
Retrieved from PubMed and FDA labeling, read on Oct 15, 2026.
- Lippi G, et al. Influence of hemolysis on routine clinical chemistry testing. Clin Chem Lab Med 2006. doi:10.1515/CCLM.2006.054
- Eisenhauer EA, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009. doi:10.1016/j.ejca.2008.10.026
- Floyd J, Mirza I, Sachs B, Perry MC. Hepatotoxicity of chemotherapy. Semin Oncol 2006. doi:10.1053/j.seminoncol.2005.11.002
- FDA label: etoposide injection (renal dose modification; no hepatic table; albumin and bilirubin warnings).
The drugs that raise platelets
Four drugs, one receptor
They all copy thrombopoietin and tell the marrow to make platelets. Eltrombopag can raise liver enzymes: check them. All of them carry a small thrombosis signal, more so in liver disease and in cancer.
Chemotherapy-induced thrombocytopenia: what changed
Prophylactic transfusion threshold without bleeding: 10,000. Before a lumbar puncture or central line, most services use 50,000 and 20,000 respectively (Kaufman 2015). Check the local policy.
Sources
Retrieved from PubMed and FDA labeling, read on Oct 15, 2026.
- Al-Samkari H, et al. Romiplostim versus placebo for chemotherapy-induced thrombocytopenia (RECITE). N Engl J Med 2026. doi:10.1056/NEJMoa2511882
- Soff GA, et al. Romiplostim treatment of chemotherapy-induced thrombocytopenia. J Clin Oncol 2019. doi:10.1200/JCO.18.01931
- Kaufman RM, et al. Platelet transfusion: a clinical practice guideline from the AABB. Ann Intern Med 2015. doi:10.7326/M14-1589
- FDA labels: romiplostim (Nplate), eltrombopag (Promacta), avatrombopag (Doptelet), lusutrombopag (Mulpleta).